# Boehringer — media coverage

Boehringer was mentioned 5 times in 5 outlets over the last 12 months.

- Data as of: 2026-10-04 (window: last 365 days)
- Mentions (12 months): 5 (10 all-time)
- Outlets (12 months): 5 in 2 countries
- Sector: Pharma

## Coverage over time (mentions per month)

| Month | Mentions |
|---|---|
| 2025-11 | 0 |
| 2025-12 | 0 |
| 2026-01 | 0 |
| 2026-02 | 1 |
| 2026-03 | 0 |
| 2026-04 | 1 |
| 2026-05 | 1 |
| 2026-06 | 1 |
| 2026-07 | 0 |
| 2026-08 | 1 |
| 2026-09 | 0 |
| 2026-10 | 0 |

## Top outlets (12 months)

| Outlet | Mentions |
|---|---|
| biospace.com | 1 |
| doh.gov.ae | 1 |
| newscenter.purina.com | 1 |
| pharmexec.com | 1 |
| prnewswire.com | 1 |

## Share of voice among Pharma peers (12 months)

| Brand | Mentions |
|---|---|
| Eli lilly | 130 |
| Astrazeneca | 78 |
| Pfizer | 64 |
| Johnson & johnson | 59 |
| Novo nordisk | 46 |
| Merck | 44 |
| Sandoz | 41 |
| Moderna | 38 |
| Bayer | 36 |
| Roche | 36 |

## Recent coverage

- [News | Department of Health - Abu Dhabi - Department of Health Abu Dhabi](https://www.doh.gov.ae/en/news/boehringer-ingelheim-and-doh-partner-to-advance-research-into-genetic-drivers-of-diseases-) — doh.gov.ae, 2026-08-27, positive
- [ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction - BioSpace](https://www.biospace.com/drug-development/boehringer-leans-on-fat-mass-benefits-as-obesity-bet-delivers-less-competitive-weight-reduction) — biospace.com, 2026-06-08, negative
- [Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis - PR Newswire](https://www.prnewswire.com/news-releases/brainomix-and-boehringer-ingelheim-advance-strategic-partnership-in-pulmonary-fibrosis-302768599.html) — prnewswire.com, 2026-05-12, positive
- [Purina Pro Plan Veterinary Announces Nationwide Call to Thank a Veterinarian - newscenter.purina.com](https://newscenter.purina.com/2026-04-22-Purina-Pro-Plan-Veterinary-Announces-Nationwide-Call-to-Thank-a-Veterinarian) — newscenter.purina.com, 2026-04-22, neutral
- [Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program - Pharmaceutical Executive](https://www.pharmexec.com/view/boehringer-ingelheim-acquires-exclusive-license-sitryx-therapeutics-preclinical-small-molecule-program) — pharmexec.com, 2026-02-26, positive

Data: VoilàIQ, 2026-10-04. Canonical: https://voilaiq.com/brand-catalog/boehringer